Aesthetic distributor DermaFocus has launched a new polynucleotide-based product, NewGlyn, to its portfolio.
According to the company, the product is designed specifically to improve damaged and degraded skin with a loss of elasticity in the female intimate area.
NewGyn has been clinically proven to reduce itching, irritation, soreness, dryness and sagging, which will lessen discomfort and help make sexual intercourse less painful, notes the company.
NewGyn comprises of 20mg of highly-purified polynucleotide technology and 20mg of non-cross linked hyaluronic acid in each 2ml syringe. Depending on the severity of patients’ symptoms, patients are advised to undergo a series of three to six treatments, spaced two to three weeks apart, every six months, adds DermaFocus.
The treatment works by regenerating fibroblasts, helping to repair damage, maintain structure and reduce sagging. The hyaluronic acid also moisturises the area to reduce dryness and discomfort, adds the company.
Milad Bemana, executive director of DermaFocus, said, “We are proud to introduce NewGyn to the UK, which offers women a fantastic minimally invasive and hormone-free treatment that can relieve them of multiple intimate health concerns. Research has found that NewGyn is a reliable stand-alone procedure, while also being capable of boosting results of other vulvo-vaginal treatments.”
